Cervical intraepithelial neoplasia in human immunodeficiency virus-positive patients.
Cervical intraepithelial neoplasia (CIN) is common in patients positive for human immunodeficiency virus (HIV). The questions are whether the management of CIN in these patients should be different from that of HIV-negative women, whether there are any prognostic factors to indicate the course of CIN, and whether the latter is influenced by antiretroviral therapy. A total of 267 HIV-seropositive women were counseled and examined in our colposcopic clinic. Of that number, 53 patients died during the observation period; 74% of these patients were immunosuppressed (CD4 count < 200 cells/mm3), and 45% were given diagnoses of CIN. The incidence of CIN was significantly higher in patients with CD4 less than 200 cells/mm3. Neither the route of HIV infection nor the HPV status nor smoking habits correlated with CIN. CIN relapse was histologically confirmed in 28% of patients who underwent complete surgical removal. Immune status plays an important role in HIV-positive women not only with respect to survival but with respect to CIN.
Ahr
A
A
Department of Gynecology and Obstetrics, Johann-Wolfgang-Goethe-University, Frankfurt, Germany.
Scharl
A
A
Lütke
K
K
Staszewski
S
S
Kacer
P Z
PZ
Kaufmann
M
M
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D011379:Prognosis; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000453:epidemiology / Q000276:immunology; D002578:Uterine Cervical Dysplasia / Q000150:complications* / Q000453:epidemiology / Q000276:immunology
D019380:Anti-HIV Agents